Latest Health News

ECP Emerging Growth Limited has reported a stable financial position for its convertible notes in Q3 2025, with a loan-to-value ratio of just 21.54% and no changes to the conversion price.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

Catapult Sports is set to acquire German soccer analytics innovator IMPECT, backed by a A$150 million equity raise, enhancing its global sports technology platform with proprietary scouting insights.

Hydrix Limited will have its trading suspension lifted on 13 October 2025 following the release of its audited financial statements for FY2025. Investors await clarity on the company’s financial health as it returns to the ASX.

Ardiden Ltd’s trading suspension has been lifted following its announcement of a significant gold acquisition and a capital raising initiative, signaling a pivotal moment for the company’s growth strategy.

Pacgold Limited’s trading suspension has been lifted following its announcement of a capital raising, signaling renewed market activity for the gold explorer.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

DPM Metals reports solid third quarter production growth at its Bulgarian mines and steady progress integrating the newly acquired Vareš operation, setting the stage for future expansion.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

LDR Assets, led by the Lederer Family Office, updates its $0.70 per security takeover offer for Elanor Commercial Property Fund, highlighting management concerns and urging investors to accept before the 13 October deadline.